Patricia Grabowski
YOU?
Author Swipe
View article: Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW)
Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW) Open
Real-world data (RWD) play a crucial role in identifying key subgroups and assessing multimodal oncology therapies, including integrative and palliative care. Immune checkpoint blockade (ICB) has improved survival, and its combination with…
View article: Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study
Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study Open
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare malignancies deriving from the endocrine system in the gastrointestinal tract including the pancreas. Prognosis is greatly heterogenous due to its dependency on various fa…
View article: Tolerability and Effectiveness of Combined Immune Checkpoint Blockade and Helixor® Viscum album Therapy in Oncological Patients: Real-World Evidence in Line with Esmo Grow Guidelines
Tolerability and Effectiveness of Combined Immune Checkpoint Blockade and Helixor® Viscum album Therapy in Oncological Patients: Real-World Evidence in Line with Esmo Grow Guidelines Open
Background: Real-world data (RWD) play a crucial role in clinical research by identifying key subgroups and assessing multimodal therapies in oncology, including integrative and (early) palliative care. Recent advancements in immune checkp…
View article: Serum Spike Protein Persistence Post COVID Is Not Associated with ME/CFS
Serum Spike Protein Persistence Post COVID Is Not Associated with ME/CFS Open
Background/Objectives: According to the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), an estimated 3–6% of people suffer from post-COVID condition or syndrome (PCS). A subset meets the diagnostic cri…
View article: Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence
Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence Open
Background: Recent advancements in cancer treatment have shown the potential of immune checkpoint blockade (ICB) plus Viscum album L. therapy in improving survival rates for patients with advanced or metastatic non-small-cell lung cancer (…
View article: Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study
Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study Open
View article: Long-term serum spike protein persistence but no correlation with post-COVID syndrome
Long-term serum spike protein persistence but no correlation with post-COVID syndrome Open
According to the World Health Organization (WHO) and the Centers for Diseases Control and Prevention (CDC), currently an estimated 3 – 6 % of people suffer from post-COVID condition or syndrome (PCS). A subset meets diagnostic criteria for…
View article: PD-1/PD-L1 Blockade Combined with AbnobaViscum<sup>®</sup>Therapy is Linked to Improved Survival in Advanced or Metastatic NSCLC Patients, an ESMO-GROW Related Real-World Data Registry Study
PD-1/PD-L1 Blockade Combined with AbnobaViscum<sup>®</sup>Therapy is Linked to Improved Survival in Advanced or Metastatic NSCLC Patients, an ESMO-GROW Related Real-World Data Registry Study Open
Background Recent advancements in cancer treatment have shown the potential of PD-1/PD-L1 inhibitor (ICB) plus Viscum album L. (VA) therapy in improving survival rates for patients with advanced or metastasized non-small cell lung cancer (…
View article: Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells Open
Introduction: Somatostatin analogues (SSAs) are commonly used in the treatment of hormone hypersecretion in neuroendocrine tumors (NETs), however the extent to which they inhibit proliferation is much discussed. Objective: We studied the a…
View article: Efficacy of Repeat Immunoadsorption in Post-COVID ME/CFS Patients with Elevated Β2-Adrenergic Receptor Autoantibodies: A Prospective Cohort Study
Efficacy of Repeat Immunoadsorption in Post-COVID ME/CFS Patients with Elevated Β2-Adrenergic Receptor Autoantibodies: A Prospective Cohort Study Open
View article: Self-Reported Baseline Quality of Life Mirrors Treatment-Specific Characteristics of Cancer Patients
Self-Reported Baseline Quality of Life Mirrors Treatment-Specific Characteristics of Cancer Patients Open
Background: Baseline quality of life (bQL) has been shown to be a predictor of the clinical outcome of oncological patients. The primary objective of the present study was to examine the role of bQL as a treatment predictor in oncological …
View article: Does the Argentine Tango Sustainably Improve Cancer-Associated Fatigue and Quality of Life in Breast Cancer Survivors?
Does the Argentine Tango Sustainably Improve Cancer-Associated Fatigue and Quality of Life in Breast Cancer Survivors? Open
Background: Chronic cancer-related fatigue is difficult to manage in breast cancer survivors. The tango trial showed that a six-week tango Argentino program was effective in reducing fatigue and improving quality of life, and here we inves…
View article: 1432P Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
1432P Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry Open
View article: Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Neuroendocrine Phenotype and mutational status NT-3
View article: Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Supplementary Methods
View article: Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with …
View article: Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
SSTR expression original tumor
View article: Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Cytokeratin expression profile NT-3 xenograft
View article: Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Morphology of NT-3
View article: Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Supplementary Methods
View article: Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Liver metastasis model NT-3
View article: Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with …
View article: Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Liver metastasis model NT-3
View article: Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Growth characteristics of BON, AGP and NT-3
View article: Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Morphology of NT-3
View article: Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
SSTR expression original tumor
View article: Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Growth characteristics of BON, AGP and NT-3
View article: Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Neuroendocrine Phenotype and mutational status NT-3
View article: Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Cytokeratin expression profile NT-3 xenograft
View article: Retrospective Analysis of the Correlation between TMD, Headache and Bruxism
Retrospective Analysis of the Correlation between TMD, Headache and Bruxism Open
Aims: To evaluate the association between bruxism, headaches, and temporomandibular disorder (TMD). Methods: A keyword search of the clinical notes of patients’ charts in AxiUmTM was performed using the search terms “TMD”, “headache”, and …